FDA Rethinking Weight Loss Standards: A Test Case for Patient-Focused Drug Development
This article was originally published in RPM Report
Executive Summary
The Center for Drug Evaluation & Research is working with George Washington University as a “neutral convener” to rethink weight loss drug development standards. That may make for an unexpected legacy from the wave of failed weight loss candidates from 2010: a whole new approach to drug development guidance from FDA.
You may also be interested in...
Obesity Therapy Gap Or Regulatory Gap? REMS Not The Answer For Belviq Or GW Group
A common theme in FDA’s review of three different weight loss drugs has been discussion of whether a Risk Evaluation & Mitigation Strategy program can help assure appropriate use of the therapies. FDA clearly thinks the answer is “no.” But that doesn’t end the discussion of what tools can be used to help curb off-label use.
Commissioner Hamburg on R&D Productivity
The following is an excerpt from FDA Commissioner Margaret Hamburg’s keynote address to the Food & Drug Law Institute annual meeting in Washington April 4.
The Future of Drug Regulation: An Interview With Center for Drug Evaluation & Research Director Janet Woodcock
FDA’s top drug regulator sat down for us for an interview about the agency’s efforts to build a higher quality regulatory system in the US—one that focuses on the “content” of regulatory standards rather than just the process. The discussion touched on the need for new and improved standards in classes like weight loss and rheumatology (albeit for very different reasons); the characteristics that make for good drug reviewers (and their managers); and on the drug center’s responsibility for preserving private sector drug development.